- Trials with a EudraCT protocol (72)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
72 result(s) found for: Kineret.
Displaying page 3 of 4.
EudraCT Number: 2018-005046-10 | Sponsor Protocol Number: HEMSC42 | Start Date*: 2019-07-23 | ||||||||||||||||
Sponsor Name:Radboud university medical center | ||||||||||||||||||
Full Title: Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic s... | ||||||||||||||||||
Medical condition: Febrile neutropenia and mucositis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005507-39 | Sponsor Protocol Number: DICTAT-1 | Start Date*: 2022-03-17 | |||||||||||||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||||||||||||
Full Title: DECIPHERING IL-1 MEDIATED INFLAMMATION FOR THE TARGETED TREATMENT OF DILATED CARDIOMYOPATHY. | |||||||||||||||||||||||
Medical condition: Inflammatory dilated cardiomyopathy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002390-28 | Sponsor Protocol Number: INSPIRE | Start Date*: 2022-10-10 | ||||||||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | ||||||||||||||||||
Full Title: IMMUNOTHERAPY NAVIGATED BY SERUM PRESEPSIN FOR INFECTIONS OF THE RESPIRATORY TRACT: THE INSPIRE DOUBLE-BLIND, RANDOMIZED, PHASE IIa EXPLORATORY TRIAL | ||||||||||||||||||
Medical condition: community-acquired pneumonia, hospital-acquired pneumonia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001963-10 | Sponsor Protocol Number: 2020-CHITS-003 | Start Date*: 2020-05-12 |
Sponsor Name:Centre Hospitalier Intercommunal de Toulon La Seyne-sur-mer | ||
Full Title: Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation: Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib | ||
Medical condition: Covid-19 disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001039-29 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-01 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL | |||||||||||||
Medical condition: Organ dysfunction by the novel SARS-Cov-2 virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005768-74 | Sponsor Protocol Number: ImmunoSep | Start Date*: 2021-02-18 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: PERSONALIZED IMMUNOTHERAPY IN SEPSIS: A MULTICENTRE AND MULTINATIONAL, DOUBLE-BLIND, DOUBLE-DUMMY RANDOMIZED CLINICAL TRIAL (THE IMMUNOSEP TRIAL) | |||||||||||||
Medical condition: Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) NL (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001500-41 | Sponsor Protocol Number: COV-AID | Start Date*: 2020-04-03 |
Sponsor Name:University Hospital Ghent | ||
Full Title: A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard ... | ||
Medical condition: COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001748-24 | Sponsor Protocol Number: ImmCoVA | Start Date*: 2020-05-15 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treat... | ||
Medical condition: COVID-19 infection in patients with respiratory distress. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002715-41 | Sponsor Protocol Number: P130934 | Start Date*: 2015-08-11 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: KAWAKINRA study, "A phase IIa multicenter trial to assess the efficacy and safety of Anakinra in patients with intraveinous immunoglobulin-resistant Kawasaki disease" | |||||||||||||
Medical condition: Anakinra treatment is expected to reduce the early and long term mortality of patients with Kawasaki Disease (KD), by a rapid and sustained effect on vascular inflammation | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001550-27 | Sponsor Protocol Number: CACZ885A2201 | Start Date*: 2006-10-20 |
Sponsor Name:Novartis Farmaceútica | ||
Full Title: Estudio aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos, con búsqueda de dosis, de 12 semanas de duración para evaluar la eficacia, la seguridad, y la tolerabi... | ||
Medical condition: Artritis reumatoide activa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) AT (Completed) BE (Completed) FI (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005804-27 | Sponsor Protocol Number: 15-200 | Start Date*: 2016-06-04 | |||||||||||
Sponsor Name:CHU CAEN | |||||||||||||
Full Title: Essai randomisé, contrôlé, en double aveugle, de l'anakinra contre placebo, en adjonction à la corticothérapie dans l'artérite à cellules géantes. | |||||||||||||
Medical condition: Patients atteints d’artérite à cellules géantes (ou maladie de Horton) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005828-11 | Sponsor Protocol Number: SAVE-MORE | Start Date*: 2020-12-16 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE-MORE DOUBLE-BLIND, RANDOMIZED, PHASE III CONFIRMATORY TRIAL | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002171-26 | Sponsor Protocol Number: PROVIDE | Start Date*: 2017-10-20 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: A PERSONALIZED RANDOMIZED TRIAL OF VALIdATION AND RESTORATION OF IMMUNE DYSFUNCTION IN SEVERE INFECTIONS AND SEPSIS: THE PROVIDE TRIAL | |||||||||||||
Medical condition: A TRIAL FOR IMMUNOMODULATION IN SEPSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001849-13 | Sponsor Protocol Number: 2013/cardio3 | Start Date*: 2013-07-09 |
Sponsor Name:ASLTO2-Maria Vittoria Hospital Cardiology | ||
Full Title: AnakInRa Treatment of Recurrent Idiopathic Pericarditis | ||
Medical condition: idiopathic recurrent pericarditis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004419-11 | Sponsor Protocol Number: SC35 | Start Date*: 2017-04-20 | ||||||||||||||||
Sponsor Name:Radboud university medical center | ||||||||||||||||||
Full Title: Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem c... | ||||||||||||||||||
Medical condition: Mucositis and febrile neutropenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001454-40 | Sponsor Protocol Number: JDRF AWARD#6-2006-1098 | Start Date*: 2007-08-02 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: A multi-step trial towards single donor islet transplantation in type I diabetic patients,using calcineurin inhibotor-free immunosuppression. | |||||||||||||
Medical condition: tipe I dyabete | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004786-80 | Sponsor Protocol Number: ANAKIN | Start Date*: 2019-02-20 | |||||||||||
Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty | |||||||||||||
Full Title: A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis. | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006644-27 | Sponsor Protocol Number: CARR-ARDS-2021 | Start Date*: 2023-02-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE | |||||||||||||
Full Title: Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study. | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000102-25 | Sponsor Protocol Number: PRECISION | Start Date*: 2023-05-30 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: SAFETY AND EFFICACY OF ANAKINRA TREATMENT FOR PATIENTS WITH PERSISENT RESPIRATORY SYMPTOMS POST ACUTE COVID AND IMMUNE SYSTEM ACTIVATION: THE PRECISION DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL | |||||||||||||
Medical condition: Post-acute COVID-19 syndrome (PACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001466-11 | Sponsor Protocol Number: SAVE | Start Date*: 2020-04-15 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL | |||||||||||||
Medical condition: Lower respiratory tract infection by Covid-19 at high risk for development of severe respiratory failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
